Markets:

Overview

News

Currencies

International

Treasuries

Agenus Inc. - Common Stock (NQ:AGEN)

4.380 +0.090 (+2.10%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Agenus Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

AGENUS INC (NASDAQ:AGEN) Reports Mixed Q3 2025 Earnings, Driven by One-Time Gain ↗

November 10, 2025

Agenus reports mixed Q3 2025 results with a revenue miss but strong clinical progress for its cancer drug BOT/BAL, including a new Phase 3 trial.

Via Chartmill

Earnings Scheduled For November 10, 2025 ↗

November 10, 2025

Via Benzinga

Insights Ahead: Agenus's Quarterly Earnings ↗

November 07, 2025

Via Benzinga

Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High

November 06, 2025

San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025....

Via MarketMinute

Topics Intellectual Property

Monday's pre-market session: top gainers and losers ↗

August 11, 2025

Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Via Chartmill

Examining the Future: Agenus's Earnings Outlook ↗

August 08, 2025

Via Benzinga

Agenus Posts 48% Q2 Revenue Miss ↗

August 11, 2025

Via The Motley Fool

12 Health Care Stocks Moving In Monday's Intraday Session ↗

July 07, 2025

Via Benzinga

Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang ↗

June 04, 2025

Zydus acquires two Agenus biologics facilities in California for $75 million, expanding U.S. CDMO presence and securing rights to key cancer drug manufacturing.

Via Benzinga

Agenus Stock Is Trading Higher Tuesday: What's Going On? ↗

June 03, 2025

Agenus announced it signed a partnership agreement with Zydus Lifesciences to expand patient access to Botensilimab and Balstilimab.

Via Benzinga

Tuesday's pre-market session: top gainers and losers ↗

June 03, 2025

The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Via Chartmill

Earnings Scheduled For May 12, 2025 ↗

May 12, 2025

Via Benzinga

Agenus's Earnings: A Preview ↗

May 09, 2025

Via Benzinga

Earnings Scheduled For November 12, 2024 ↗

November 12, 2024

Via Benzinga

Earnings Scheduled For August 11, 2025 ↗

August 11, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

June 03, 2025

Via Benzinga

Why Credo Technology Group Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket ↗

June 03, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

May 12, 2025

Via Benzinga

Here are the top movers in Tuesday's session. ↗

April 22, 2025

Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session.

Via Chartmill

Insights Ahead: Agenus's Quarterly Earnings ↗

November 11, 2024

Via Benzinga

Agenus (AGEN) Q4 2024 Earnings Call Transcript ↗

March 11, 2025

AGEN earnings call for the period ending December 31, 2024.

Via The Motley Fool

Topics Earnings

Earnings Scheduled For March 11, 2025 ↗

March 11, 2025

Via Benzinga

Agenus Gets $22M Mortgage, Plans Strategic Realignment To Focus On Colorectal Cancer Drug Development ↗

November 27, 2024

Agenus secures a $22M mortgage and announces a strategic realignment to focus on botensilimab/balstilimab in MSS colorectal cancer.

Via Benzinga

Agenus (AGEN) Q3 2024 Earnings Call Transcript ↗

November 12, 2024

AGEN earnings call for the period ending September 30, 2024.

Via The Motley Fool

Topics Earnings

GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults ↗

September 18, 2024

GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The study showed a non-inferior immune response and good safety profiles. The...

Via Benzinga

Agenus (AGEN) Q2 2024 Earnings Call Transcript ↗

August 08, 2024

AGEN earnings call for the period ending June 30, 2024.

Via The Motley Fool

Topics Earnings

AGEN Stock Earnings: Agenus Misses EPS, Misses Revenue for Q2 2024 ↗

August 08, 2024

AGEN stock results show that Agenus missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

Via InvestorPlace

Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus ↗

August 05, 2024

Agenus reports that Bristol Myers Squibb (NYSE: BMY) is ending their 2021 agreement, returning the TIGIT bispecific antibody AGEN1777. This decision is part of Bristol Myers' broader pipeline strategy...

Via Benzinga

Agenus Faces Regulatory and Financial Challenges: Analyst Downgrades Stock Pending Trial Clarity ↗

July 19, 2024

Agenus faces a setback as the FDA advises against accelerated approval for its immunotherapy combination, botensilimab and balstilimab, for relapsed/refractory microsatellite-stable colorectal cancer....

Via Benzinga

Nasdaq Down Over 100 Points; Abbott Laboratories Earnings Beat Views ↗

July 18, 2024

Via Benzinga

Topics Earnings

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Agenus Inc. - Common Stock (NQ:AGEN)

Headline News about Agenus Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today